AI drug discovery
-
Genesis Therapeutics Rakes In $200M For AI-Powered Drug Discovery
Genesis Therapeutics recently joined the growing list of AI-powered drug discovery startups receiving venture funding this year. The company closed a $200 million Series B financing round, taking its total funding to date to more than $280 million.
-
MedCity Influencers, Artificial Intelligence
Better Predicting Drug Safety Calms Quarrels Between Medical Needs & Regulatory Process
Human tissues, coupled with AI that can deal with terabytes of data will blow mice models out of the water. With animal testing requirements finally removed, the pharma industry and its constituents can hope for faster innovation.
-
Payer’s Place: Dawn Maroney
Dawn Maroney, President, Markets of Alignment Health and CEO of Alignment Health Plan, to discuss how they are using technology to provide better service and care to consumers.
-
MedCity Influencers, Artificial Intelligence
Smart Medicine: Artificial Intelligence is Shaping Drug Discovery and Development in Ways Never Once Imagined
Traditionally, pharmaceutical companies have been slow to adopt these newer technologies, instead relying on well-established and proven – but usually complex – manufacturing processes. However, the time to begin investing in – and exploring – AI, machine learning, and big data is now.
-
Artificial Intelligence, BioPharma
BioNTech Dives Deeper Into Digital With £362M Buyout of AI Startup InstaDeep
BioNTech says its InstaDeep acquisition will help it expand its use of artificial intelligence in drug discovery and development. The startup specializes in a type of machine learning called reinforcement learning.
-
Artificial Intelligence, BioPharma
Sanofi Inks Another AI Alliance, This Time Partnering With Insilico Medicine
Sanofi will use Insilico Medicine’s tech to advance drug development candidates for up to six new targets. Disease indications were not disclosed, but the pharmaceutical giant said the new agreement will boost its drug discovery research in China.
-
Versant-founded biotech Nested hatches with $90M and new take on cancer drugs
Nested Therapeutics uses computational techniques to map mutations and protein structures, identifying previously unseen places where a cancer drug can bind. The Versant Ventures-founded startup is now out of stealth with two programs on the path to the clinic.
-
Artificial Intelligence, BioPharma
Biotech startup with AlphaGo-type AI approach snags $30M
The CEO of Anagenex believes that the company’s AI engine trained on billions of data points and iterative testing will blow other AI drug discovery startups out of the water.
-
Pharma, Artificial Intelligence, BioPharma
GSK joins LifeMine’s $175M funding, reviving fungi as a drug discovery frontier
LifeMine Therapeutics, a company that analyzes fungal genomes to find molecules that have potential as new medicines, has raised $175 million in financing. Among the investors is GlaxoSmithKline, which is teaming up with the biotech startup in a multi-target drug discovery alliance.
-
Artificial Intelligence, BioPharma
Creyon Bio gets some green for a new take on AI and genetic meds R&D
Creyon Bio is the latest company to launch with artificial intelligence technology for drug R&D. The startup claims its technology can provide sufficient safety and toxicity data to enable a therapy to bypass the animal research currently needed before clinical trials.
-
Applying Remote Patient Monitoring to Surgery Prep and Recovery, Oncology and Women’s Health
Join us to learn about the latest trends in remote monitoring and how to extend its benefits beyond chronic conditions to more patients – all while using fewer staff resources.
-
Artificial Intelligence, BioPharma
Flagship’s Vesalius launches with $75M to take AI into realm of common diseases
Artificial intelligence is a powerful tool for rare disease drug discovery. The founders of Vesalius Therapeutics say AI and machine learning can also be applied to common diseases, and the startup has launched with $75 million in committed financing.
-
Artificial Intelligence, BioPharma
AI-biotech Terray emerges with $60M and a solution for data problems in drug R&D
Terray Therapeutics uses tiny microarrays to test molecules against targets of interest, then applies artificial intelligence to build large chemical datasets. The startup’s Series A financing will support R&D initially in immunology; the first Terray molecule is expected to reach the clinic in 18 months.
-
Daily, Artificial Intelligence, BioPharma
With 3 inflammation drugs on path to the clinic, Ventus Therapeutics adds $140M
Ventus Therapeutics’ lead programs address pathways associated with inflammation. Led by CEO Marcelo Bigal, the biotech discovers its drugs using computational analysis to understand the structure of proteins and find small molecules that can hit these “undruggable” targets.
-
Pharma, Artificial Intelligence, BioPharma
Sanofi bets big on AI again, paying $100M to start drug R&D pact with Exscientia
Sanofi’s new alliance with artificial intelligence biotech Exscientia spans up to 15 small molecule drugs in cancer and immunology. If drugs from the partnership reach the market, Exscientia could earn as much as $5.2 billion in milestone payments.
-
Artificial Intelligence, BioPharma, Legal
DeepMind has unlocked protein-based medicine – what does that mean for drug patents?
One of science’s great puzzles is being solved by artificial intelligence and the answers shared freely on the internet. How can life sciences companies make the most of DeepMind’s discoveries while protecting their own?
-
Artificial Intelligence, BioPharma
HiberCell’s Genuity buyout brings $100M, plus alliances with Ionis and AbbVie
Startup HiberCell has acquired Genuity Science, a marriage that brings together two companies that apply AI and machine learning to drug research. HiberCell says Genuity will help the company identify and validate new pathways in how cancer starts and progresses.
Promoted
Payer’s Place: Dr. Anil Singh
Dr. Anil Singh shares his insights into the strategies employed by the organization to identify the most effective digital solutions for their members.
Promoted
Discover the Next-Gen Platform for Integrated Collaborative Care
Beyond EHRs and digital front doors, reducing the gaps in patient care journeys.
